| DC22765 |
LB-102
Featured
|
LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor. |
|
| DC23329 |
LCH 7749944
Featured
|
LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members. |
|
| DC7184 |
Lcl-161
Featured
|
LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies. |
|
| DC7707 |
LCZ-696
Featured
|
LCZ696 is a first-in-class dual inhibitor of the angiotensin II receptor(AT II receptor) and neprilysin; a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). |
|
| DC9394 |
LDC000067
Featured
|
LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
|
| DC7999 |
LDC1267
Featured
|
LDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively. |
|
| DC10143 |
LDC-4297
Featured
|
LDC4297 is a novel CDK7 inhibitor. |
|
| DC8493 |
NVP-LDE225(Erismodegib)
Featured
|
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
|
| DC7185 |
LDE225 Diphosphate
Featured
|
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
|
| DC5167 |
Ceritinib(LDK378)
Featured
|
LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM |
|
| DC8231 |
LDN-192960 2HCl
Featured
|
LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm |
|
| DC7451 |
LDN-193189 HCl
Featured
|
LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. |
|
| DC8034 |
LDN193189 free base
Featured
|
LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. |
|
| DC9432 |
LDN-212320
Featured
|
LDN-212320(OSU-0212320) is a glutamate transporter EAAT2 activator; enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.
|
|
| DC7586 |
LDN-212854
Featured
|
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. |
|
| DC7914 |
LDN-214117
Featured
|
LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM). |
|
| DC7610 |
LDN-57444
Featured
|
LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3. |
|
| DC7947 |
Ledipasvir
Featured
|
Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C. |
|
| DC9773 |
LEE011 hydrochloride
Featured
|
LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|
| DC7453 |
Ribociclib (LEE011)
Featured
|
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|
| DC9774 |
LEE011 succinate
Featured
|
LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
.gif)
|
| DC12387 |
Lefamulin acetate
Featured
|
Lefamulin acetate is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections. |
|
| DC8172 |
Lefamulin(BC-3781)
Featured
|
Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is required for bacteria to grow. |
|
| DC22136 |
LEI 110
Featured
|
LEI110 (LEI－110) is a potent Phospholipase A2 group XVI (PLA2G16) inhibitor with Ki of 20 nM, also has activity on HRASLS2, RARRES3 and iNAT (pIC50=6.8-7.6). |
|
| DC12562 |
LEM-14
Featured
|
LEM-14 is a specific inhibitor of histone lysine methyltransferase NSD2 (MMSET/WHSC1) with in vitro IC50 of 132 uM, and that is inactive against the closely related NSD1 and NSD3.. |
|
| DC8173 |
Lemborexant(E2006)
Featured
|
Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia. |
|
| DCAPI1502 |
Lenalidomide
Featured
|
Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties. |
|
| DC12386 |
Leniolisib (CDZ173)
Featured
|
Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders. |
.gif)
|
| DC22302 |
Leonurine hydrochloride
Featured
|
Leonurine hydrochloride is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory. |
|
| DC10777 |
Leonurine
Featured
|
Leonurine, a natural alkaloid extracted from Herba leonuri, has been proved to have anti-inflammatory effect. |
|
